Top 10 Challenges: Producing commercial cell and gene products

whitePaper | January 4, 2022

The Biotechnology Innovation Organization (BIO) appreciates the opportunity to participate in the 2022 Special 301 Review: Identification of Countries under Section 182 of the Trade Act of 1974: Request for Public Comment and Announcement of Public Hearing.

whitePaper | April 16, 2020

Accurate diagnosis is the cornerstone of medicine; it is essential for informed care and promoting patient and family well-being. However, families with a rare genetic disease (RGD) often spend more than five years on a diagnostic odyssey of specialist visits and invasive testing that is lengthy, costly, and often futile, as 50% of patients do not receive a molecular diagnosis.

whitePaper | October 12, 2022

Advanced therapy medicinal products cell and gene therapies offer tremendous hope for patients either by actually curing serious diseases or by alleviating suffering.

whitePaper | February 24, 2022

Sustainable fungal materials have a high potential to replace non-sustainable materials such as those used for packaging or as an alternative for leather and textile.

whitePaper | June 10, 2022

Healthcare is changing rapidly. Companies who provide products and services to hospitals and physicians will need to adjust their operations to change.

whitePaper | October 27, 2022

The cell and gene therapy (CGT) market is rapidly transitioning from ultra-niche cutting-edge science to approved and available therapies that can address previously intractable and often devastating diseases.